POTENTIAL CHANGES IN DRUG REVIEW PROCESS SHOULD NOT PREVENT "GOOD SCIENCE" AND EFFICIENT REVIEWS -- FDA's MEYER; FDA WANTS INPUT OF ACADEME ON COST STUDIES
Executive Summary
Possible changes in FDA drug review procedures should not get in the way of scientifically-sound and timely reviews of drug applications, Center for Drug Evaluation and Research Acting Director Gerald Meyer cautioned at a recent meeting of the International Industrial Pharmacy Conference in Austin, Texas.